Multiple sclerosis: Fingolimod failure in progressive MS INFORMS future trials

Andrew L. Smith, Jeffrey A. Cohen

Research output: Contribution to journalShort surveypeer-review

6 Scopus citations


Fingolimod is approved for the treatment of relapsing-remitting multiple sclerosis (MS), and evidence suggests that it has neuroprotective effects. The recent INFORMS phase III trial in primary progressive MS demonstrated no beneficial effects of fingolimod on disability progression or whole-brain atrophy, but provides important information for future therapeutic development.

Original languageEnglish (US)
Pages (from-to)253-254
Number of pages2
JournalNature Reviews Neurology
Issue number5
StatePublished - May 1 2016
Externally publishedYes

Bibliographical note

Funding Information:
A.L.S. is supported by a National Multiple Sclerosis Society Sylvia Lawry Physician Fellowship Award (FP 17117-A-2).

Publisher Copyright:
© 2016 Macmillan Publishers Limited. All rights reserved.


Dive into the research topics of 'Multiple sclerosis: Fingolimod failure in progressive MS INFORMS future trials'. Together they form a unique fingerprint.

Cite this